Biomed 101
Alternative Names: Biomed101Latest Information Update: 24 Oct 2021
At a glance
- Originator Pfizer
- Class Chemoprotectants
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Renal cancer
Most Recent Events
- 01 Oct 2004 BioMedicines is now called Intarcia Therapeutics
- 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the adverse events and Cancer pharmacodynamics sections
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer